Genentech reiterated at buy by Jefferies

Jefferies & Co., Inc. analyst Adam Walsh reiterated Genentech, Inc. at a buy and a $106 price target. A survey by the analyst revealed that formal Food and Drug Administration approval of Herceptin for adjuvant breast cancer will increase use. Approval is expected on Nov. 16. Shares of the South San Francisco, Calif.-based biotherapeutic company were up 28 cents, or 0.35%, at $80.72. (NYSE: DNA)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.